Inovio Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors
I'm PortAI, I can summarize articles.
Inovio Pharmaceuticals Inc. (INO) shares fell 24.45% to $1.73 on Monday, marking a significant decline amid a broader market downturn, with the NASDAQ and Dow Jones also experiencing losses. This drop ended a two-day winning streak and left the stock 41.92% below its 52-week high of $2.98. Inovio's performance lagged behind competitors like Johnson & Johnson and Pfizer, while Statera Biopharma saw a remarkable 200% increase. Trading volume reached 6.1 million, significantly higher than its 50-day average of 1.3 million.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Dow Jones The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments